Immunomodulation for the Prevention and Treatment of Lung Infections

Seminars in Respiratory and Critical Care Medicine

Volumn 25, Issue 1, 2004, Pages 95-108

  Standiford, Theodore J ^a,b   Deng, Jane C ^b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cytokines; Immunotherapy; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BCG VACCINE; CD40 LIGAND; COLONY STIMULATING FACTOR; CORTICOSTEROID; CYTOKINE; DINUCLEOTIDE; DNA VACCINE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INTERLEUKIN 10; INTERLEUKIN 12; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PNEUMOCOCCUS CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; POLYCLONAL ANTIBODY; RECOMBINANT CD40 LIGAND; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; STAPHYLOCOCCUS VACCINE; STREPTOCOCCUS VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VACCINE;

ACTIVE IMMUNIZATION; ANTIMICROBIAL THERAPY; BACTERIAL PNEUMONIA; CLINICAL TRIAL; EFFECTOR CELL; GENE THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; LUNG INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTE; PRIORITY JOURNAL; REVIEW;

EID: 1542363530     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822309     Document Type: Review

References (120)

1. Davies J. Inactivation of antibiotics and dissemination of resistance genes. Science 1994;264:375-382
2. Update CDC. Stapbylococcus aureus resistant to vancomycin-United States, 2002. MMWR, Morb Mortal Wkly Rep 2002;51:565-567
3. Toews GB, Gross GN, Pierce AK. The relationship of inoculum size to lung bacterial clearance and phagocytic cell response in mice. Am Rev Respir Dis 1979;120:559-566
4. Nelson S, Mason CM, Kolls JK. Pathophysiology of pneumonia. Clin Chest Med 1995;16:1-12
5. Moore TA, Moore B, Standiford TJ. Gamma delta T cells are required for protective innate immune responses in murine Klebsiella pneumonia. J Immunol 2000;165:2643-2650
6. Malaviya R, Ikeda T, Ross E, Abraham SN. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 1996;2:381:21-22
7. Standiford TJ, Huffnagle GB. Cytokines in host defense against pneumonia. J Invest Med 1997;45:335-345
8. Reddy RC, Chen GH, Tekchandana PK, Standiford TJ. Sepsis-induced immunosuppression. Immunol Res 2001;24:273-287
9. Volk HD, Reinke P, Docke WD. Clinical aspects: from systemic inflammation to "immunoparalysis". Chem Immunol 2000;74:162-177
10. Appel SH, Wellhausen SR, Montgomery R, et al. Experimental and clinical significance of endotoxin-dependent HLA-DR expression on monocytes. J Surg Res 1989;47:39-44
11. Munoz C, Carlet J, Fitting C, et al. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-1754
12. Tracey KJ, Beutler B, Lowry SF, Cerami A. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-474
13. News and Comment. IL-12 deaths: explanation and the puzzle. Science 1995;270:908
14. Wilson JM. Molecular medicine: adenoviruses as gene-delivery vehicles. N Engl J Med 1996;334:1185-1187
15. Roilides E, Walsh TJ, Pizzo PA, et al. G-CSF enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991;163:579-583
16. Hebert JC, O'Reilly M, Gamelli RL. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 1990;125:1075-1078
17. Nelson S, Summer W, Bagby G, et al. Granulocyte colony-stimuating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J. Infect Dis 1991;164:901-906
18. Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE. Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995;86:1301-1309
19. Dierdorf R, Kreuter U, Jones TC. A role for granulocyte-macrophage colony-stimulating factor (GM-CSF) in the treatment of neutropenic patients with pneumonia. Braz J Infect Dis 1997;1:68-76
20. Keiser P, Rademacher S, Smith JW, et al. Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 1998;104:48-55
21. Gruson D, Hilbert G, Vargas F, et al. Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients. Crit Care Med 2000;28:3155-3160
22. Nelson S, Belnap SM, Carlson RW, et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 1998;178:1075-1080
23. Nelson S, Heyder AM, Stone J, et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 2000;182:970-973
24. Wunderink RG, Leeper KV Jr, Schein R, et al. Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001;119:523-529
25. Berdaz P-Y, Shibata Y, Whitsett JA, Trapnell BC. GMCSF, via PU.1, regulates alveolar macrophage FcγR-mediated phagocytosis and the IL-18/IFN-γ-mediated molecular connection between innate and adaptive immunity in the lung. Blood 2002;100:4193-4200
26. Levine AM, Reed JA, Kurak KE, Cianciolo E, Whisett JA. GM-CSF deficient mice are susceptible to pulmonary group B streptococcal infection. J Clin Invest 1999;103:563-569
27. Paine R III, Preston AM, Wilcoxen S, et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J Immunol 2000;164:2602-2609
28. Manfredi R, Mastroianni MR, Coronado O, Chiodo F. Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in leukopenic patients with advanced HIV disease. J Chemother 1996;8:214-220
29. Hebert JC, O'Reilly M. Granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances pulmonary defenses against pneumococcal infections after splenectomy. J Trauma 1996;41:663-666
30. Nierhaus A, Montag B, Timmler N, et al. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis. Intensive Care Med 2003;29:646-651
31. Presneill JJ, Harris T, Stewart A, et al. A randomized phase II trail of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002;166:138-143
32. Jenson W, Rose R, Wasserman A, Kalb T, Anton K, Remold H. In vitro activation of the antibacterial activity of human pulmonary macrophages by recombinant gamma interferon. J Infect Dis 1987;155:574-577
33. Ahlin A, Elinder G, Palmblad J. Dose-dependent enhancements by interferon-gamma on functional responses of neutrophils from chronic granulomatous disease patients. Blood 1997;89:3396-3401
34. Rubins JB, Pomeroy C. Role of gamma interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect Immun 1997;65:2975-2977
35. Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-1949
36. Jounanguy E, Altare F, Lamhamedi S, et al. Interferon-gamma receptor deficiency in an infant with fatal bacilli Calmette-Guérin infection. N Engl J Med 1996;335:1956-1961
37. Beck J, Liggitt H, Brunette E, Fuchs H, SheUito J, Debs R. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991;59:3859-3862
38. Skerrett S, Martin T. Intratracheal interferon-γ augments pulmonary defenses in experimental legionellosis. Am J Respir Crit Care Med 1994;149:50-58
39. Lei D, Lancaster JR, Joshi MS, et al. Activation of alveolar macrophages and lung host defenses using transfer of the interferon-gamma gene. Am J Physiol 1997;272:L852-L859
40. Deng J, Tateda K, Zeng X, Standiford TJ. Transient transgenic expression of IFN-7 promotes Legionella pneumophila clearance in immunocompetent hosts. Infect Immun 2001;69:6382-6390
41. Johnston RB Jr. Clinical aspects of chronic granulomatous disease. Curr Opin Hematol 2001;8:17-22
42. Conte D, FraqueUi M, Capsoni F, et al. Effectiveness of IFN-gamma for liver abscesses in chronic granulomatous disease. J Interferon Cytokine Res 1999;19:705-710
43. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 1997;3:678-681
44. Honore I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003;167:953-957
45. Brunda M. Interleukin-12. J Leukoc Biol 1994;55:280-288
46. Chehimi J, Trinchieri G. Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency. J Clin Immunol 1994;14:149-159
47. Greenberger MJ, Kunkel SL, Strieter RM, et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996;157:3006-3012
48. deJong R, Altare F, Haagen IA, et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 1998;280:1435-1438
49. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, Wolf S, Bloom BR. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J Immunol 1995;155:2515-2524
50. Kawakami K, Tohyama M, Xie Q, Saito A. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996;104:208-214
51. O'Brien CB, Moonka DK, Henzel BS, et al. A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-alpha. Am J Gastroenterol 2001;96:2473-2479
52. Jacobson MA, Spritzler J, Landay A, et al. A phase 1, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. AIDS 2002;16:1147-1154
53. Rolph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, T lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808-814
54. Howard M, O'Garra A, Ishida H, Malefyt RD, De Vries J. Biological properties of interleukin 10. J Clin Immunol 1992;12:239-247
55. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993;177:1205-1208
56. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL. Neutralization of IL-10 increases lethality in endotoxemia: cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995;155:2222-2229
57. Bermudez LE, Champsi J. Infection with Mycobacterium avium induces production of interleukin-10 (IL-10), and administration of anti-IL-10 antibody is associated with enhanced resistance to infection in mice. Infect Immun 1993;61:3093-3097
58. Greenberger MJ, Strieter RM, Kunkel SL, Danforth J, Goodman R, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722-729
59. van der Poll T, Marchant A, Keogh C, Goldman M, Lowry S. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000
60. Steinhauser ML, Hogboam CM, Kunkel SL, Lukacs N, Strieter RM, Standiford TJ. IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 1999;162:392-399
61. Sawa T, Corry DB, Gropper MA, Ohara M, Kurahashi K, Wiener-Kronish JP. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J Immunol 1997;159:2858-2866
62. Morrison DF, Foss DL, Murtaugh MP. Interleukin-10 gene therapy amelioration of bacterial pneumonia. Infect Immun 2000;68:4752-4758.
63. Qureshi MH, Harmsen AG, Garvy BA. IL-10 modulates host responses and lung damage induced by Pneumocystis carinii infection. J Immunol 2003;170:1002-1009
64. MacFadden DK, Edelson JD, Hyland RH, Rodriquez CH, Inouye T, Rebuck AS. Corticosteroids as adjuvant therapy in the treatment of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet 1987;1:1477-1479
65. Laman JD, Claasen E, Noelle RJ. Functions of CD40 and its ligand, gp39 (CD40L). Crit Rev Immunol 1996;16:59-70
66. + CTL response. J Exp Med 1996;183:2129-2137
67. Oz HS, Hughes WT, Rehg JE, Thomas EK. Effect of CD40 ligand and other immunomodulators on Pneumocystis carinii infection in rat model. Microb Pathog 2000;29:187-190
68. Tripp RA, Jones L, Anderson LJ, Brown MP. CD40 ligand (CD154) enhances the Thl and antibody responses to respiratory synctial virus in the BALB/c mouse. J Immunol 2000;164:5913-5921
69. Kikuchi T, Hackett NR, Crystal RG. Cross-strain protection against clinical and laboratory strains of Pseudomonas aeruginosa mediated by dendritic cells genetically modified to express CD40 ligand and pulsed with specific strains of Pseudomonas aeruginosa. Hum Gene Ther 2001;12:1251-1263
70. + T cells. Nat Med 2000;6:1154-1159
71. + cell-independent vaccination against Pneumocystis carinii in mice. J Clin Invest 2001;108:1469-1474
72. Krieg A. The role of CpG motifs in innate immunity. Curr Opin Immunol 2000;12:35-43
73. Hayashi T, Rao SP, Takabayashi K, et al. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,-dioxygenase. Infect Immun 2001;69:6156-6164
74. Freidag BL, Melton GB, Collins F, et al. CpG oligodeoxynudeotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis. Infect Immun 2000;68:2948-2953
75. Pal S, Davis HL, Peterson EM, de la Maza LM. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun 2002;70:4812-4817
76. Hancock GE, Heers KM, Smith JD, et al. CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV). Vaccine 2001;19:4874-4882
77. Rose SC, McCool T, Greenspan NS, et al. CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun 2000;68:1450-1456
78. Gross PA. Vaccines for pneumonia and new antiviral therapies. Med Clin North Am 2001;85:1531-1544
79. Eskola J, Antitila M. Pneumococcal conjugate vaccines. Pediatr Infect Dis J 1999;18:543-551
80. Fedson DS, Wajda A, Nicol P, et al. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993;270:1956-1961
81. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-784
82. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat Biotechnol 1999;17:1075-1081
83. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002;346:491-496
84. Trolle S, Chachaty E, Kassis-Chikhani N, et al. Intranasal immunization with protein-linked phosphorylcholine protects mice against a lethal intranasal challenge with Streptococcus pneumonia. Vaccine 2000;18:2991-2998
85. Cahill E, O'Hagan D, Illum L, et al. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 1995;13:455-462
86. Prideaux CT, Lenghaus C, Krywult J, et al. Vaccination and protection of pigs against pleuropneumonia with a vaccine-strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII peron. Infect Immun 1999;67:1962-1966
87. Bandholtz L, Kreuger MR, Svanholm C, Wigzell H, Rottenberg ME. Adjuvant modulation of the immune responses and the outcome of infection with Chlamydia pneumoniae. Clin Exp Immunol 2002;130:393-403
88. Pascale JM, Shaw MM, Durant PJ, et al. Intranasal immunization confers protection against murine Pneumocystis carinii lung infection. Infect Immun 1999;67:805-809
89. Mallett CP, Hale TL, Kaminski RW, et al. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection. Infect Immun 1995;63:2382-2386
90. Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly (DL-lactide-coglycolide) microspheres. Infect Immun 1995;63:1195-1200
91. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenzavirus vaccine in healthy working adults. JAMA 1999;282:137-144
92. McDonnell WM, Askari FK. Molecular medicine: DNA vaccines. N Engl J Med 1996;334:42-45
93. Penttila T, Vuola JM, Puurula V, et al. Immunity to Chlamydia pneumoniae induced by vaccination with DNA vectors expressing a cytoplasmic protein (Hsp60) or outer membrane proteins (MOMP and Omp2). Vaccine 2000;19:1256-1265
94. Zhang D, Yang X, Berry J, et al. DNA vaccination with the major outer-membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J Infect Dis 1997;176:1035-1040
95. Lai WC, Pakes SP, Ren K, et al. Therapeutic effect of DNA immunization of genetically susceptible mice infected with virulent Mycoplasma pulmonis. J Immunol 1997;158:2513-2516
96. Chen Y-L, Wang S-N, Yang W-J, et al. Expression and immunogenicity of Mycoplasma hyopneumoniae heat shock protein antigen P42 by DNA vaccination. Infect Immun 2003;71:1155-1160
97. + T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J Immunol 1998;160:2425-2432
98. Tascon RE, Colston MJ, Ragno S, et al. Vaccination against tuberculosis by DNA injection. Nat Med 1996;2:888-892
99. Svanholm C, Bandholtz L, Castanos-Velez E, et al. Protective DNA immunization against Chlamydia pneumoniae. Scand J Immunol 2000;51:345-353
100. Okada E, Sasaki S, Ishii N, et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159:3638-3647
101. Polack FP, Lee SH, Permar S, et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 2000;6:776-781
102. Skerrett SJ. Antibody treatment of lower respiratory tract infections. Semin Respir Infect 2001;16:67-75
103. Rosen FS, Cooper MD, Wedgewood RJ. The primary immunodeficiencies. N Engl J Med 1995;333:431-440
104. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-117
105. deHennezel L, Ramisse F, Binder P, et al. Effective combination therapy for invasive Pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model. Antimicrob Agents Chemother 2001;45:316-318
106. Landsperger WJ, Kelly-Wintenberg KD, Montie TC, et al. Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat. Infect Immun 1994;62:4825-4830
107. Saravolatz LD, Markowitz N, Collins MS, Bogdanoff D, Pennington JE. Safety, pharmacokinetics, and functional activity of human anti-Pseudomonas aeruginosa monoclonal antibodies in septic and non-septic patients. J Infect Dis 1991;164:803-806
108. Glass I, Schorer R. Adjuvant therapy with Pseudomonas immunoglobulin in artificially ventilated patients at a surgery intensive care unit. Anaesth Intensive Care 1989;24:167-171
109. Cometta A, Baumgartner J-D, Lee ML, et al. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992;327:234-240
110. Just HM, Metzger M, Vogel W, et al. Effect of adjuvant immunoglobulin therapy on infections in patients in a surgical intensive care unit: results of a randomized controlled study. Klin Wochenschr 1986;64:245-256
111. de Simone C, Delogu G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit Care Med 1988;16:23-26
112. Dominioni L, Dionigi R, Zanello M, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991;126:236-240
113. Harrison FJ, Rohm D, Kohzuki T, et al. Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients. Hybridoma 1997;16:413-420
114. Comette A, Baumgartner JD, Glauser MP. Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients. Clin Exp Immunol 1994;97:69-72
115. Kelly J. Immunotherapy against antibiotic-resistant bacteria: the Russian experience with an antistaphylococcal hyper-immune plasma and immunoglobulin. Microbes Infect 2000;2:1383-1392
116. Reed EC, Bowden RA, Dandliker PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783-788
117. Whimbley E, Champlin RE, England JA, et al. Combination therapy with aerosolized ribavivrin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16:393-399
118. Casadevall A, Feldmesser M, Pirofski LA. Induced humoral immunity and vaccination against major human fungal pathogens. Curr Opin Microbiol 2002;5:386-391
119. Gigliotti F, Haidaris GC, Wright TW, Harmsen AG. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun 2002;70:1069-1074
120. Ramisse F, Binder P, Szatanik M, et al. Passive and active immunotherapy for experimental pneumococcal pneumonia by polyvalent human immunoglobulin or F(ab′)2 fragments administered intranasally. J Infect Dis 1996;173:1123-1128